← All reports

Biotech & Longevity · week of 10 Aug – 16 Aug

Biotech & Longevity: 10 Aug – 16 Aug

Pressure climbed 8 points across the week, 58 to 66.

66

pressure at the week’s end, 0–100

+8

move across the week

7

editions published

114

sources read behind them

The arc · 7 days with a board

The band each day fell in.

No written analysis for this week

Everything on this page is measured from the week’s own boards and editions. The written read is added when the engine runs its report pass; a week without one still has its record.

What we said to watch

10 Aug Whether regulators and clinics start recommending a cheap gene test before prescribing drugs like antidepressants and certain chemotherapies, the direction a New Zealand primary-care pilot points.

The beat ended the week Two-speed.

11 Aug Whether the daily obesity pill widens access at November's UK cost ruling, and whether tightening oversight of gene-editing trials slows the run of firsts.

The beat ended the week Two-speed.

12 Aug Whether regulators start demanding proof that new screening tests actually lower cancer deaths, not just find more cancer, before backing them.

The beat ended the week Two-speed.

13 Aug Whether gene therapies keep crossing barriers that blocked drugs for decades - the inner ear, muscle, the brain - or whether getting the drug there stays the wall that stops good molecules from reaching patients.

The beat ended the week Two-speed.

14 Aug Whether US states actually loosen the rules requiring vaccines before school - that, more than the order itself, is what would let coverage fall far enough to widen the measles outbreak.

The beat ended the week Two-speed.

15 Aug Whether the order cutting childhood vaccine doses survives the states and doctors' groups now rejecting it: US measles is already at a 35-year high, and coverage slipping a few points below about 95% is what turns scattered cases back into outbreaks.

The beat ended the week Two-speed.

16 Aug Watch whether the childhood vaccine order signed on 10 August actually changes what doctors give children, because that is the one thing on this beat that would reach ordinary families directly, and measles is already at a 35-year high.

The beat ended the week Two-speed.

The honest half. These are the markers the boards named at the time — kept on the record whether or not they turned out to matter.

The board on Monday, and the board at the end

Opened

10 Aug

Precision medicine 64
Cancer immunotherapy 74
AI in drug discovery 56
Biology fights back 70
Drug safety and oversight 52
Drugs reaching hard diseases 34

Ended

16 Aug

Vaccine policy fight 84
Approvals landing 78
Single-drug bets 72
The making is the hard part 66
Hope ahead of proof 58
Money for rare disease 36

Both boards exactly as they were written at the time — not a diff. The engine names the forces fresh every morning, so "The cheap-yen gap" on Monday and "Money leaving the dollar" on Friday may well be the same pressure under different words. Comparing the labels would measure the labels; comparing the two boards yourself is the honest version.

The week’s editions · 7

Biotech 16 Aug · 22 SRC

A new class of cancer drug wins approval by changing a protein's shape

Biotech 15 Aug · 18 SRC

One dose, twelve weeks: an LSD-based drug clears a second phase 3 for anxiety

Biotech 14 Aug · 16 SRC

A vaccine order lands as measles hits a 35-year high, and the math of the crowd

Biotech 13 Aug · 15 SRC

A deafness gene therapy reaches a child, in a week ruled by the delivery problem

Biotech 12 Aug · 15 SRC

A blood test that hunts 50 cancers reaches the FDA, and the math that decides what a positive means

Biotech 11 Aug · 16 SRC

The weight-loss pill arrives, and it rewrites how often you dose

Biotech 10 Aug · 12 SRC

The gene that decides who suffers side effects from antidepressants

The same week, another beat

Everything World Finance Tech Mind & body Climate Space Biotech Money Sports Gaming Food Cyber